| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8615352 | Clinical Lymphoma Myeloma and Leukemia | 2018 | 9 Pages |
Abstract
Overall, data from the PANEX trial support regulatory approval of panobinostat plus bortezomib and dexamethasone and suggest the potential tolerability benefits of subcutaneous bortezomib in this regimen.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Vincent L. Hansen, Morton Coleman, Stephanie Elkins, Jeffrey P. Letzer, Moshe Yair Levy, Lasika Seneviratne, Jessica Rine, Marina White, Emil T. Kuriakose,